智通财经APP讯，瑞丽医美(02135)发布公告，于2024年1月24日，公司与Suneva 订立供货协议，据此，公司将收购分销权及股权。
公告称，集团的主要业务为提供医疗美容服务。Suneva 拥有或控制若干与贝丽菲尔相关的自主知识产权。收购分销权旨在确保Suneva 于供货协议期限内向集团供应贝丽菲尔及向集团授出贝丽菲尔于大中华区的独家分销权。收购股权将加强集团与Suneva 的长期合作。因此，集团拟透过收购事项拓展其于医疗美容服务行业的供应链，并获得稳定可靠的贝丽菲尔供应。董事认为，收购事项将促进集团的业务营运及加强公司将于大中华区销售的贝丽菲尔的供应。
由于管理层的无意疏忽，公司未就收购事项作出申报及公告。因此，收购事项未遵守上市规则第14章的规定。公司承认，无意违反上市规则实属疏忽所致，并重申其相信持续遵守上市规则及其他适用监管规定至关重要。负责人员日后于订立任何可构成公司须予公布的交易之协议前应取得必要批准及╱或同意。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.